<--- Back to Details
First PageDocument Content
Pharmaceutical industry / Muscular dystrophy / Clinical trial / Design of experiments / Pharmacology / Disease registry / Spinal muscular atrophy / TREAT-NMD / Duchenne muscular dystrophy / Medicine / Health / Clinical research
Date: 2015-02-25 01:48:12
Pharmaceutical industry
Muscular dystrophy
Clinical trial
Design of experiments
Pharmacology
Disease registry
Spinal muscular atrophy
TREAT-NMD
Duchenne muscular dystrophy
Medicine
Health
Clinical research

Australian NMD Registry Consent Form Version[removed]

Add to Reading List

Source URL: nmdregistry.com.au

Download Document from Source Website

File Size: 443,53 KB

Share Document on Facebook

Similar Documents

PROUD PROUD Participant Involvement meeting: Trial Design Date: Tuesday 9th September – 20.00 Venue: MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, Holborn, WC2B 6NH Contact person: Mitzy Gaf

DocID: 1vq4y - View Document

Clinical Review & Education JAMA | Special Communication Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols

DocID: 1vmrb - View Document

For immediate release March 21, 2017 Infectex Announces Positive Phase 2b-3 Clinical Trial Results of SQ109 for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis Moscow, Russia and Rockville, MD, USA -- Infecte

DocID: 1vkmw - View Document

DEPARTMENT OF HEALTH DRUG OFFICE DRUG REGISTRATION AND IMPORT/EXPORT CONTROL DIVISION Guidance Notes on the Application for Certificate for Clinical Trial/Medicinal Test Background

DocID: 1vkj3 - View Document

CLINICAL TRIAL OUTCOME DATABASE (CTOD) Novartis RA: Longitudinal Model-Based Meta-Analysis in Rheumatoid Arthritis: An Application Toward Model-Based Drug Development Authors I Demin, B Hamren, O Luttringer, G Pillai and

DocID: 1vbDv - View Document